Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 ZP Qureshi, E Seoane‐Vazquez, R Rodriguez‐Monguio, KB Stevenson, ... Pharmacoepidemiology and drug safety 20 (7), 772-777, 2011 | 189 | 2011 |
Incentives for orphan drug research and development in the United States E Seoane-Vazquez, R Rodriguez-Monguio, SL Szeinbach, J Visaria Orphanet journal of rare diseases 3, 1-7, 2008 | 184 | 2008 |
Dispensing errors in community pharmacy: perceived influence of sociotechnical factors S Szeinbach, E Seoane-Vazquez, A Parekh, M Herderick International Journal for Quality in Health Care 19 (4), 203-209, 2007 | 108 | 2007 |
The impact of allergic rhinitis on work productivity SL Szeinbach, EC Seoane-Vazquez, A Beyer, PB Williams Primary Care Respiratory Journal 16 (2), 98-105, 2007 | 87 | 2007 |
The landscape of cellular and gene therapy products: authorization, discontinuations, and cost V Shukla, E Seoane-Vazquez, S Fawaz, L Brown, R Rodriguez-Monguio Human gene therapy clinical development 30 (3), 102-113, 2019 | 86 | 2019 |
Incorporating indications into medication ordering—time to enter the age of reason G Schiff, E Seoane-Vazquez, A Wright | 83 | 2016 |
Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? R Rodriguez-Monguio, T Spargo, E Seoane-Vazquez Orphanet journal of rare diseases 12, 1-8, 2017 | 74 | 2017 |
Innovation and competition in advanced therapy medicinal products E Seoane‐Vazquez, V Shukla, R Rodriguez‐Monguio EMBO molecular medicine 11 (3), e9992, 2019 | 70 | 2019 |
Exogenous endoscopy-related infections, pseudo-infections, and toxic reactions: clinical and economic burden E Seoane-Vazquez, R Rodriguez-Monguio, J Visaria, A Carlson Current medical research and opinion 22 (10), 2007-2021, 2006 | 70 | 2006 |
Approval and withdrawal of new antibiotics and other antiinfectives in the US, 1980–2009 K Outterson, JH Powers, E Seoane‐Vazquez, R Rodriguez‐Monguio, ... The Journal of Law, Medicine & Ethics 41 (3), 688-696, 2013 | 62 | 2013 |
Using a machine learning system to identify and prevent medication prescribing errors: a clinical and cost analysis evaluation R Rozenblum, R Rodriguez-Monguio, LA Volk, KJ Forsythe, S Myers, ... The Joint Commission Journal on Quality and Patient Safety 46 (1), 3-10, 2020 | 61 | 2020 |
Endoscopy-related infections and toxic reactions: an international comparison E Seoane-Vazquez, R Rodriguez-Monguio, J Visaria, A Carlson Endoscopy, 742-778, 2007 | 59 | 2007 |
Endoscopy-related infection: relic of the past? E Seoane-Vazquez, R Rodriguez-Monguio Current opinion in infectious diseases 21 (4), 362-366, 2008 | 53 | 2008 |
Incorporating medication indications into the prescribing process K Kron, S Myers, L Volk, A Nathan, P Neri, A Salazar, MG Amato, A Wright, ... The Bulletin of the American Society of Hospital Pharmacists 75 (11), 774-783, 2018 | 44 | 2018 |
International critical care hospital pharmacist activities JM LeBlanc, EC Seoane-Vazquez, TC Arbo, JF Dasta Intensive care medicine 34, 538-542, 2008 | 43 | 2008 |
Fixed-dose combination drug approvals, patents and market exclusivities compared to single active ingredient pharmaceuticals J Hao, R Rodriguez-Monguio, E Seoane-Vazquez PloS one 10 (10), e0140708, 2015 | 40 | 2015 |
Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals? S Alqahtani, E Seoane‐Vazquez, R Rodriguez‐Monguio, T Eguale Pharmacoepidemiology and Drug Safety 24 (7), 709-715, 2015 | 40 | 2015 |
Evaluation of causes and frequency of medication errors during information technology downtime TL Hanuscak, SL Szeinbach, E Seoane-Vazquez, BJ Reichert, ... American Journal of Health-System Pharmacy 66 (12), 1119-1124, 2009 | 36 | 2009 |
Cost-effectiveness analysis of metformin+ dipeptidyl peptidase-4 inhibitors compared to metformin+ sulfonylureas for treatment of type 2 diabetes CS Kwon, E Seoane-Vazquez, R Rodriguez-Monguio BMC health services research 18, 1-12, 2018 | 35 | 2018 |
Good research practices for measuring drug costs in cost‐effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force … CD Mullins, B Seal, E Seoane‐Vazquez, J Sankaranarayanan, CV Asche, ... Value in Health 13 (1), 18-24, 2010 | 35 | 2010 |